163 related articles for article (PubMed ID: 19629010)
1. Use of biologic agents in pediatric inflammatory bowel disease.
Rosh JR
Curr Opin Pediatr; 2009 Oct; 21(5):646-50. PubMed ID: 19629010
[TBL] [Abstract][Full Text] [Related]
2. Treatment with biologic therapies and the risk of cancer in patients with IBD.
Biancone L; Calabrese E; Petruzziello C; Pallone F
Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):78-91. PubMed ID: 17268543
[TBL] [Abstract][Full Text] [Related]
3. Use of biological molecules in the treatment of inflammatory bowel disease.
Nielsen OH; Seidelin JB; Munck LK; Rogler G
J Intern Med; 2011 Jul; 270(1):15-28. PubMed ID: 21241384
[TBL] [Abstract][Full Text] [Related]
4. Translating inflammatory bowel disease research into clinical medicine.
Neurath MF; Finotto S
Immunity; 2009 Sep; 31(3):357-61. PubMed ID: 19766078
[TBL] [Abstract][Full Text] [Related]
5. [Must immunomodulators be added to biological treatment in inflammatory bowel disease?].
Gomollón F; Gisbert JP
Gastroenterol Hepatol; 2010 Jan; 33(1):43-53. PubMed ID: 19616870
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
Reddy JG; Loftus EV
Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
[TBL] [Abstract][Full Text] [Related]
8. Management consensus of inflammatory bowel disease for the Asia-Pacific region.
Ouyang Q; Tandon R; Goh KL; Pan GZ; Fock KM; Fiocchi C; Lam SK; Xiao SD
J Gastroenterol Hepatol; 2006 Dec; 21(12):1772-82. PubMed ID: 17074013
[TBL] [Abstract][Full Text] [Related]
9. Drug therapy for inflammatory bowel disease in pregnancy and the puerperium.
Moffatt DC; Bernstein CN
Best Pract Res Clin Gastroenterol; 2007; 21(5):835-47. PubMed ID: 17889811
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
Lichtenstein GR; Diamond RH; Wagner CL; Fasanmade AA; Olson AD; Marano CW; Johanns J; Lang Y; Sandborn WJ
Aliment Pharmacol Ther; 2009 Aug; 30(3):210-26. PubMed ID: 19392858
[TBL] [Abstract][Full Text] [Related]
11. Adverse effects of biologics used for treating IBD.
Stallmach A; Hagel S; Bruns T
Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):167-82. PubMed ID: 20227030
[TBL] [Abstract][Full Text] [Related]
12. [Biologic therapy for inflammatory bowel diseases].
Bosques Padilla F
Rev Gastroenterol Mex; 2006 Aug; 71 Suppl 1():91-4. PubMed ID: 17037786
[No Abstract] [Full Text] [Related]
13. Safety issues with biological therapies for inflammatory bowel disease.
Van Assche G; Vermeire S; Rutgeerts P
Curr Opin Gastroenterol; 2006 Jul; 22(4):370-6. PubMed ID: 16760752
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing the relapse of patients with inflammatory bowel disease.
Miner PB
Am J Gastroenterol; 1997 Dec; 92(12 Suppl):1S-4S. PubMed ID: 9395345
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
Markowitz J; Grancher K; Mandel F; Daum F
Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
[TBL] [Abstract][Full Text] [Related]
16. Use of tumor necrosis factor inhibitors in uveitis.
Rabinovich CE
Curr Opin Rheumatol; 2007 Sep; 19(5):482-6. PubMed ID: 17762615
[TBL] [Abstract][Full Text] [Related]
17. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents.
Kwon JH; Farrell RJ
Crit Rev Oncol Hematol; 2005 Oct; 56(1):169-78. PubMed ID: 15979323
[TBL] [Abstract][Full Text] [Related]
18. Optimizing therapy for inflammatory bowel disease.
Robinson M
Am J Gastroenterol; 1997 Dec; 92(12 Suppl):12S-17S. PubMed ID: 9395347
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
[TBL] [Abstract][Full Text] [Related]
20. Maximizing the effect of biologics in inflammatory bowel disease.
Souto Rodriguez R; Swoger JM; Barreiro-De Acosta M; Regueiro M
Minerva Gastroenterol Dietol; 2012 Jun; 58(2):101-22. PubMed ID: 22643594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
